Approval · Notice of Compliance 20652 · 2018
QTERN: Notice of Compliance 20652
Issued March 22, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20652
- Date
- March 22, 2018
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to product monograph in response to health canada issued advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| QTERN | Not yet assigned | — |
Medicinal ingredients
- DAPAGLIFLOZIN 5 MG per TAB
- SAXAGLIPTIN 5 MG per TAB
- DAPAGLIFLOZIN 10 MG per TAB